A proton pump inhibitor
Tegoprazan is a proton pump inhibitor that inhibits H+/K+-ATPase activity in porcine gastric membrane vesicles (IC50 = 0.53 ?M).1 It completely inhibits basal gastric acid secretion in pylorus-ligated rats when administered at a dose of 10 mg/kg and reduces esophageal mucosal tissue levels of myeloperoxidase (MPO), a marker of tissue damage, in a rat model of reflux esophagitis (ED50 = 5.9 mg/kg). Tegoprazan reduces ulcer area in rat models of gastric ulcers induced by naproxen, water-immersion restraint stress (WIRS), or ethanol (ED50s = 0.1, 0.1, and 1.4 mg/kg, respectively).
1.Kim, D.K., Lee, K.-H., Kim, S.-J., et al.Effects of tegoprazan, a novel potassium-competitive acid blocker, on rat models of gastric acid-related diseaseJ. Pharmacol. Exp. Ther.369(3)318-327(2019)
动态评分
0.0